NewsMay 5, 2026
Lunai Bioworks Raises $20 Million to Acquire CNS Drug Delivery Technology for Alzheimer's Treatment
Lunai Bioworks completes $20M preferred equity raise to acquire CNS delivery tech and neurotherapeutic IP, expanding Alzheimer's disease treatment platform.
Dr. Yuki Tanaka
